Reports Q3 revenue $380.8M, consensus $375.78M. “Our third-quarter results highlight the early progress we are making to identify and remediate the gaps in our quality management system,” said Jan De Witte, president and CEO of Integra LifeSciences (IART). “We are progressing with the implementation of our compliance master plan across our manufacturing and supply chain operations, which will position us to meet robust market demand and more consistently and reliably deliver to customers, patients, and shareholders.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra Lifesciences (IART) Q3 Earnings Cheat Sheet
- Integra LifeSciences price target lowered to $21 from $26 at Truist
- Integra LifeSciences price target lowered to $18 from $26 at BofA
- Integra LifeSciences upgraded to Neutral from Sell at BTIG
- Integra LifeSciences price target lowered to $16 from $20 at Citi